Download Material Safety Data Sheet (MSDS)

PENN VECTOR CORE
Gene Therapy Program
Department of Pathology and Laboratory Medicine
MATERIAL INFORMATION SHEET Adenoviral Vectors: General Information Adenoviral vectors consist of recombinant transgene sequences (e.g. encoding reporter or therapeutic genes) inserted at E1 region of an E1 or E1‐E3‐deleted adenoviral backbones. The E1 deletion renders the vector replication ‐defective and dependent upon E1 and other viral sequences present in human 293 cells. Adenoviral cultures are normally provided as purified viral particles in phosphate buffered saline. The viral stock consists of particles containing the vector genome (infectious particles) and a variable number of empty viral capsids in PBS. Other trace components present include, but are not limited to, inorganic salts, vitamins and other nutrients, and human cellular proteins, carbohydrates, amino acids, and fats. The material is normally shipped and stored frozen. MATERIAL SAFETY DATA SHEET (MSDS) E1‐deleted adenoviral vectors are non‐infectious, non‐hazardous and replication defective (unless passaged in a permissive cell line), as defined by OSHA 1919.1200. Adenoviral vectors are, however, produced in cells where there is the possibility of recombination to form wild type virus and so should be handled as potentially infectious material. The vectors should be used under biosafety level (BSL)– 2 conditions. Routine quality control on preclinical vectors includes determination of physical genome titer and yield, determination of infectious titer, endotoxin analysis and DNA structure analysis. SECTION I ‐ IDENTITY NAME: Recombinant adenoviral vector, Type 5 SYNONYM OR CROSS REFERENCE: adenoviral vector, H5 vector, Ad5 vector CHARACTERISTICS: Adenoviridae; non‐enveloped, icosahedral virions, 75 – 80 nm diameter, double‐stranded, linear DNA genome. Recombinant vectors are based on the human type 5 adenoviral backbone which is deleted in the essential E1 gene as well as the E3 gene. The vectors produced are therefore non‐replicative. SECTION II – HEALTH HAZARD PATHOGENICITY: Wild type adenovirus infection varies in clinical manifestation and severity; symptoms include fever, rhinitis, pharyngitis, cough and conjunctivitis. The risk from infection by defective recombinant adenoviral vectors depends on the level of wild type virus generated (if any) and the nature of the transgene. Adenoviruses and adenoviral vectors can produce a strong immune response; they do not integrate into the host cell genome. HOST RANGE: Humans and animals INCUBATION PERIOD: 1 – 10 days MODE OF TRANSMISSION: In the laboratory, care must be taken to avoid spread of infectious material by aerosol, direct contact or accidental injection. TRL Suite 2000, 125 S 31st Street | Philadelphia PA 19104-3403 | Tel: 215-573-0633|Fax: 215-261-2442
PENN VECTOR CORE
Gene Therapy Program
Department of Pathology and Laboratory Medicine
SECTION III – VIABILITY DRUG SUSCEPTIBILITY: No specific antiviral available SUSCEPTIBILITY TO DISINFECTANTS: Susceptible to 1% sodium hypochlorite, 2% glutaraldehyde, 10% chlorine bleach; Recommended use of 10% (final concentration) chlorine bleach for 10 min. SURVIVAL OUTSIDE THE HOST: Adenovirus type 5 can survive 3 – 8 weeks on environmental surfaces at room temperature SECTION IV – RECOMMENDED PRECAUTIONS CONTAINMENT REQUIREMENTS: Biosafety level 2 practices and containment facilities for all activities involving the vector and potentially infectious body fluids or tissues. PROTECTIVE CLOTHING: Laboratory coat, gloves, eye protection OTHER PRECAUTIONS: Limited access to laboratory SECTION V – HANDLING INFORMATION HANDLING: Handle as biohazardous material under Biosafety Level 2 containment DISPOSAL: Dispose of viral stock by autoclaving at 121 C for 30‐45 minutes; Dispose of infected liquid cultures by decontamination with chlorine bleach (10% f.c.) for 10 minutes and then dispose of in sink; Dispose of infected animal carcasses or tissues by incineration STORAGE: Sealed containers that are appropriately labelled; ‐80 C long term storage recommended For information on BSL‐2 handling, see Biosafety in Microbiological and Biomedical Laboratories (BMBL) 5th Edition The above information is accurate to the best of our knowledge and experience. The user should exercise independent judgment as to the hazards based on all sources of information available. For current MSDS information, please visit the Penn Vector Core website. TRL Suite 2000, 125 S 31st Street | Philadelphia PA 19104-3403 | Tel: 215-573-0633|Fax: 215-261-2442